247 related articles for article (PubMed ID: 20028747)
41. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
42. PI3K/Akt and mTOR/p70S6K pathways mediate neuroprotectin D1-induced retinal pigment epithelial cell survival during oxidative stress-induced apoptosis.
Faghiri Z; Bazan NG
Exp Eye Res; 2010 Jun; 90(6):718-25. PubMed ID: 20230819
[TBL] [Abstract][Full Text] [Related]
43. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
Yu K; Shi C; Toral-Barza L; Lucas J; Shor B; Kim JE; Zhang WG; Mahoney R; Gaydos C; Tardio L; Kim SK; Conant R; Curran K; Kaplan J; Verheijen J; Ayral-Kaloustian S; Mansour TS; Abraham RT; Zask A; Gibbons JJ
Cancer Res; 2010 Jan; 70(2):621-31. PubMed ID: 20068177
[TBL] [Abstract][Full Text] [Related]
44. Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer.
Gulhati P; Cai Q; Li J; Liu J; Rychahou PG; Qiu S; Lee EY; Silva SR; Bowen KA; Gao T; Evers BM
Clin Cancer Res; 2009 Dec; 15(23):7207-16. PubMed ID: 19934294
[TBL] [Abstract][Full Text] [Related]
45. Mammalian target of rapamycin signaling modulates photic entrainment of the suprachiasmatic circadian clock.
Cao R; Li A; Cho HY; Lee B; Obrietan K
J Neurosci; 2010 May; 30(18):6302-14. PubMed ID: 20445056
[TBL] [Abstract][Full Text] [Related]
46. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
47. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
Martelli AM; Evangelisti C; Chiarini F; Grimaldi C; Manzoli L; McCubrey JA
Expert Opin Investig Drugs; 2009 Sep; 18(9):1333-49. PubMed ID: 19678801
[TBL] [Abstract][Full Text] [Related]
48. Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved.
Bian P; Hu W; Liu C; Li L
Arch Biochem Biophys; 2020 Aug; 689():108461. PubMed ID: 32531316
[TBL] [Abstract][Full Text] [Related]
49. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.
Nagata Y; Takahashi A; Ohnishi K; Ota I; Ohnishi T; Tojo T; Taniguchi S
Int J Oncol; 2010 Oct; 37(4):1001-10. PubMed ID: 20811722
[TBL] [Abstract][Full Text] [Related]
50. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC).
Tan AC
Thorac Cancer; 2020 Mar; 11(3):511-518. PubMed ID: 31989769
[TBL] [Abstract][Full Text] [Related]
51. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
52. Antiproliferative Activity of Carnosic Acid is Mediated via Inhibition of Cell Migration and Invasion, and Suppression of Phosphatidylinositol 3-Kinases (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
Zhao L; Zhang J; Fan Y; Li Y
Med Sci Monit; 2019 Oct; 25():7864-7871. PubMed ID: 31631173
[TBL] [Abstract][Full Text] [Related]
53. Luteoloside induces G
Zhou M; Shen S; Zhao X; Gong X
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):263-269. PubMed ID: 29024631
[TBL] [Abstract][Full Text] [Related]
54. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
Burris HA
Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
[TBL] [Abstract][Full Text] [Related]
55. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
Sun Z; Wang Z; Liu X; Wang D
Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
[TBL] [Abstract][Full Text] [Related]
56. Sporoderm-Broken Spores of Ganoderma lucidum Inhibit the Growth of Lung Cancer: Involvement of the Akt/mTOR Signaling Pathway.
Chen Y; Lv J; Li K; Xu J; Li M; Zhang W; Pang X
Nutr Cancer; 2016 Oct; 68(7):1151-60. PubMed ID: 27618151
[TBL] [Abstract][Full Text] [Related]
57. Are we on the brink of nonsurgical treatment for ameloblastoma?
Sauk JJ; Nikitakis NG; Scheper MA
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Jul; 110(1):68-78. PubMed ID: 20418126
[TBL] [Abstract][Full Text] [Related]
58. Targeting the PI3K/AKT/mTOR Signaling Pathway in Lung Cancer: An Update Regarding Potential Drugs and Natural Products.
Iksen ; Pothongsrisit S; Pongrakhananon V
Molecules; 2021 Jul; 26(13):. PubMed ID: 34279440
[TBL] [Abstract][Full Text] [Related]
59. Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas.
Bhatt AP; Bhende PM; Sin SH; Roy D; Dittmer DP; Damania B
Blood; 2010 Jun; 115(22):4455-63. PubMed ID: 20299510
[TBL] [Abstract][Full Text] [Related]
60. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
